34 hvor patienterne fik behandling med fosamprenavir/ ritonavir 1 gang daglig sammenlignet med APV29005 (39%), hvor patienterne fik fosamprenavir/ ritonavir 2 gange daglig.
Drug-related adverse events were more common in APV20003 (55%) where subjects received once daily fosamprenavir / ritonavir when compared to APV29005 (39%) where subjects received twice daily fosamprenavir / ritonavir.